论文部分内容阅读
目的：评价采用Ｖｉｔａｌ－Ｐｏｒｔ系统从动脉途径对４２例临床晚期肿瘤患者进行序贯化疗的结果。材料与方法：４２例恶性肿瘤均属临床Ⅲ级患者，平均年龄５９．３岁，全身状况的Ｋａｒｎｏｆｓｋｙ评分在１０～７０分之间。从左锁骨下动脉入路，将留置导管送入靶血管后，在左锁骨下窝皮下植入Ｖｉｔａｌ－Ｐｏｒｔ。依不同肿瘤设计不同化疗方案，通过皮下药盒注射来完成，每一疗程间隔２０～３０天，连续３个疗程。结果：全部４２例Ｖｉｔａｌ－Ｐｏｒｔ系统１次植入成功，患者生活质量明显改善，超过１年累计生存率为３１．２５％，最长追踪病例为３１个月。结论：经动脉途径的序贯化疗保留了动脉内１次冲击化疗的优势，在维持小剂量高靶区血药物浓度、化疗药物配伍设计，以及药代动力学监控上具有明显的优越性，更适宜于晚期肿瘤的治疗。
OBJECTIVE: To evaluate the results of sequential chemotherapy using the Vital-Port system for 42 patients with advanced clinical tumors from the arterial route. Materials and Methods: Forty-two malignant tumors belonged to clinical grade III patients with an average age of 59.3 years. The Karnofsky score of general condition was between 10 and 70 minutes. From the left subclavian artery approach, the indwelling catheter was delivered to the target vessel and Vital-Port was implanted subcutaneously in the left subclavian fossa. According to different tumors design different chemotherapy programs, through the subcutaneous kit injection to complete, each treatment interval of 20 to 30 days, 3 consecutive courses. RESULTS: All 42 cases of Vital-Port system were implanted successfully. The quality of life of patients was significantly improved. The cumulative survival rate over 1 year was 31.25%, and the longest follow-up case was 31 months. Conclusion: The sequential chemotherapy via the arterial route retains the advantage of one-time intra-arterial infusion chemotherapy. It has obvious advantages in maintaining high-dose, high-target blood drug concentration, compatibility design of chemotherapy drugs, and monitoring of pharmacokinetics. Suitable for the treatment of advanced tumors.